Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte Aviation (NYSE American: VJET) changed its corporate name from Catheter Precision and its ticker from VTAK, effective October 5, 2026. The rebranding marks a repositioning around private aviation and its AI-driven booking platform.
Flyte plans to expand its customer network, aircraft fleet and geographic reach. During fourth-quarter 2026, it plans to invest in website and mobile application development, AI data analytics and customer acquisition. Its longer-term strategy includes connecting participants across North American private aviation, with potential acquisitions and technology development among its growth options.
Flyte says its Life Sciences operations will not be capital constrained or downsized as it directs capital toward aviation growth. It also commits to continued funding of multiple ongoing research trials and studies.
Catheter Precision (VTAK) will implement a 1-for-10 reverse stock split effective at the opening of trading on October 5, 2026.
The board approved changing the company’s name to Flyte Aviation and ticker to VJET; trading under both will begin on the same date. Outstanding common shares will fall from approximately 21.0 million to 2.1 million. Ownership percentages will remain unchanged except for fractional-share treatment, and outstanding options, warrants and convertible preferred stock will receive proportionate adjustments. The common stock remains listed on NYSE American.
Catheter Precision (VTAK) subsidiary Flyte has partnered with the Hamptons International Film Festival as its official air travel partner.
The 34th annual festival runs October 2–12, 2026, across the East End. Flyte is a lead sponsor and will have a brand presence throughout the festival. It will sponsor the World Cinema Narrative section and the 2026 Breakthrough Honors. The Flyte Breakthrough Awards will recognize performers Anthony Ippolito and Rosalind Eleazar, and director Jordan Firstman.
Catheter Precision (VTAK) is expanding commercialization of its LockeT cardiac electrophysiology product across Latin America following a successful launch in Brazil in August 2026.
LockeT was introduced in São Paulo through a distribution agreement with Ablacor and is now used in six hospitals, with additional Brazilian institutions expressing interest. To support broader regional growth, the company has engaged an experienced cardiology group with electrophysiology expertise and longstanding relationships throughout Latin America. Catheter Precision is pursuing opportunities in Argentina, Chile, Colombia and other countries, viewing early Brazilian adoption as a model for its wider international expansion strategy.
Catheter Precision (VTAK) announced a New York Fashion Week partnership between Flyte and fashion designer Christian Cowan to grow the Flyte brand.
The collaboration aligns Flyte’s private aviation platform with Christian Cowan’s globally recognized fashion label and the high‑value audience surrounding New York Fashion Week, including celebrities, executives, creators and tastemakers. Flyte aims to build a lifestyle-focused private aviation brand by integrating into culturally relevant events and communities across fashion, entertainment, sports, hospitality and luxury travel, supported by a standardized Cirrus Vision Jet fleet, a direct-to-consumer technology platform and an expanding network of strategic partnerships.
Catheter Precision (VTAK) subsidiary Flyte has received international approvals to expand private flight operations from the United States into The Bahamas and Caribbean.
The authorization allows Flyte to offer private charter services linking its growing Florida network with high-demand leisure and resort destinations across the region, using its fleet of Cirrus Vision Jets. Initial potential routes include Miami, Fort Lauderdale, Palm Beach and Naples to locations such as Nassau, Bimini, Marsh Harbour and Eleuthera. Flyte plans immediate commercialization through direct-to-consumer marketing, strategic partnerships and its existing customer base.
Catheter Precision (NYSE American: VTAK) reported key commercial milestones for its cardiac electrophysiology portfolio, including its first purchase order for the LockeT suture retention device placed through Cardinal Health, which services roughly 90% of U.S. hospitals via its medical products business.
The company also received an initial LockeT order from Johns Hopkins Hospital, a leading academic medical center, and signed its first placement contract for the VIVO 3D imaging system with a hospital in Germany, one of Europe’s largest electrophysiology markets, supporting its U.S. distribution and international expansion strategy.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), reported surpassing 10,000 consumer accounts on its private aviation WebApp, with new account creation accelerating sharply. From August 1–17, Flyte added 1,830 accounts, up about 170% from the 679 accounts added in the same July period.
Over the most recent 30 days, Flyte added 2,417 accounts, an increase of roughly 118% versus the prior 30 days, and has added 3,132 accounts in the third quarter to date compared with 1,934 during the entire first half of 2026. Nearly one in four accounts was created in the last 30 days. According to Flyte, the more than 10,000 accounts represent first-party customer relationships spanning 174 airports in 19 states, with about 6,105 accounts (around 60%) including mobile phone numbers, and are supported by 14 strategic partners across multiple premium sectors.
Catheter Precision (NYSE American: VTAK), doing business as Flyte, announced a strategic partnership with FullPAC, an AI-powered political technology platform serving more than 5,000 campaigns, SuperPACs and political organizations. Flyte becomes FullPAC’s recommended regional aviation partner, offering its Cirrus Vision Jet network to qualified congressional, Senate, gubernatorial and attorney general campaigns.
The partnership targets the $11.4 billion U.S. political campaign market for the 2026 cycle, initially focusing on high-value statewide races in Florida, New York, Pennsylvania, North Carolina, Virginia and Georgia. According to Flyte, benefits include access to FullPAC’s nationwide network, time savings via regional airports, lower operating costs versus larger jets, and expanded utilization for Flyte’s Vision Jet fleet across business, leisure and political travel segments.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic partnership with The Nucleus Network, a fast-growing community for founders, investors, executives, and innovators. Flyte will support and participate in the inaugural “The Nucleus” flagship event on August 15 at 4:00 p.m..
The event is intended to become The Nucleus Network’s signature annual gathering, convening about 200 founders, investors, operators, and strategic partners for networking, brand activations, and relationship building. According to Flyte, this partnership aligns with its strategy to connect with influential entrepreneurial and venture communities while promoting its technology-enabled private aviation services and growing fleet of Cirrus Vision Jets.